TP53 and cancer: Recently, our research team disclosed a new p53-activating anticancer drug, (3S)-6,7-bis(hydroxymethyl)-5-methyl-3-phenyl-1H,3H-pyrrolo[1,2-c]thiazole (MANIO) (Fig. 1).5 MANIO represents a privileged anticancer drug compared to other currently available p53-activating agents regarding its antitumor activity in several cancer types, including CRC.